Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

Pinto, Álvaro; Reig, Òscar; Iglesias, Clara; Gallardo, Enrique; Muro, Xavier García-Del; Alonso, Teresa; Anguera, Geòrgia; Suárez, Cristina; Muñoz-Langa, José; Villalobos-León, Laura; A, Rodriguezsanchez; Laínez, Núria; Martínez-Ortega, Esther; Campayo, Marc; Velastegui, A.; Rodríguez‐Vida, Alejo; Villa-Guzmán, José Carlos; Mendez-Vidal, María José; Rubio, Gustavo; García, I. Osmán; Capdevila, Laia; Lambea, J.; Vázquez, S.; Fernández, O.; Hernando-Polo, Susana; Cerezo, S.; Santander, Carmen; García-Marrero, Rosa; Zambrana, Francisco; Alba, Aranzazu González-del; Lázaro-Quintela, Martín; Castellano, Daniel; Chirivella, Isabel; Anido, Urbano; Viana, Ana Carolina Cavalcante; García, A. Fernández; Sotelo, Miguel; Arévalo, Maria T.; García-Donás, Jesús; Hernández, Carolina; Bolós, Maria Victoria; Llinares, Julia; Climent, Miguel Ángel

doi:10.1016/j.clgc.2021.09.006

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the results of a recent real-world AXILONG study imply that some patients with RCC might benefit from second-and subsequent-line axitinib therapy more than previously supposed. In the AXILONG study [11], median PFS in a subgroup of patients with more favorable predictive factors (older age at the start of the treatment and baseline hemoglobin greater than lower limit of normal) was 18.1 months [95% CI: 13.8, 22.5],…”

Section: Discussionmentioning

confidence: 99%

Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy

Shin¹,

Lee²,

Kwon³

et al. 2023

Cancer Res Treat

View full text Add to dashboard Cite

This post-marketing surveillance (PMS)study was conducted to monitor the usage of axitinib (Inlyta) in clinical practice of Korean patients with advanced renal cell carcinoma (RCC) with disease progression during or after a prior systemic therapy in real world. Materials and MethodsIn this multicenter, observational study, patients indicated for oral axitinib 5 mg twice daily as second-line therapy for advanced RCC were followed up under routine clinical practices, and their safety and effectiveness outcomes were collected. ResultsBetween 2012 and 2021, 125 patients were enrolled, and data from 111 patients were analyzed.Median age was 65 years (range: 30 to 84), 81% was male, and 110 (99%) had clear cell RCC.The median daily dose of axitinib was 10 mg (range: 4.36-15.95 mg) with a median administration period of 5.6 months (range: 15-750 days). 83% of patients experienced any grade of adverse events, 71% of which were related to study treatment, including diarrhea (36%), hypertension (21%), stomatitis (17%), decreased appetite (14%), palmar-plantar erythrodysesthesia syndrome (12%), and asthenia (11%). Most adverse events were generally well tolerated and manageable, with 13% of grade >3. Axitinib dose reduction was required in 20% of the adverse events and discontinuation in 8%. Median progression-free survival (PFS) was 12.4 months [95% CI: 9.6, 18.9]. Objective responses were observed in 30% of patients (95% CI: 21 to 39) with 4% of complete response and 26% of partial response. ConclusionNo new safety signal was found in the present PMS study of Korean RCC patients. Axitinib showed consistent outcomes in terms of effectiveness and safety confirming that the drug is a valid option for second-line therapy in patients with advanced RCC in a real-world setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy

Shin¹,

Lee²,

Kwon³

et al. 2023

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Axitinib

2022

Reactions Weekly

View full text Add to dashboard Cite

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population

Jakobsson,

Strambi,

Nilsson

et al. 2024

Future Oncology

View full text Add to dashboard Cite

Aim: Assess the time-to-treatment discontinuation (TTD) and overall survival (OS) in a Swedish metastatic renal cell carcinoma (mRCC) nationwide cohort who received second-line axitinib. Methods: Retrospective analysis of 110 patients with mRCC treated with second-line axitinib in Sweden (2012–2019). Patients included in the study received axitinib after mainly first-line sunitinib or pazopanib. Results: The median (95% CI) TTD of patients who received second-line axitinib was 5.2 (3.7–6.1) months with 6 (5.5%) patients still receiving treatment at the time of analysis. Median (95% CI) OS was 12.2 (7.7–14.2) months. Conclusion: The results are consistent with previous findings in mRCC and add to the evidence demonstrating efficacy of second-line axitinib, after failure of a prior anti-angiogenic therapy in a real-world setting. Clinical Trial Registration: NCT04669366 ( ClinicalTrials.gov )

show abstract

Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

Cited by 3 publications

References 35 publications

Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy

Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy

Axitinib

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population

Contact Info

Product

Resources

About